Saxenhammer & Co. advises Germany-based life-science company DYPHOX on its EUR 2.5m capital raise via private placement.
Regensburg (Germany), 15.04.2021 – Saxenhammer & Co. acted as the exclusive sell-side advisor on the capital raise via private placement of DYPHOX (TriOptoTec GmbH), a life-science company focused on highly efficient and environmentally friendly antimicrobial coating technologies from Regensburg, Germany. With this additional cash infusion, DYPHOX will intensify its marketing and sales activities in addition to its planned expansion of production to meet the ever-increasing demand.
Founded as a spin-off of the Regensburg University Hospital, DYPHOX developed a novel technology to destroy microorganisms on various surfaces with the help of photo dynamics in an efficient and environmentally friendly way. DYPHOX’s proprietary antimicrobial coating technology helps to reduce healthcare-associated infections (HCAIs) significantly and makes healthcare institutions safer and more sustainable.
The Saxenhammer & Co. deal team was led by Dr. Nicholas Hanser (Partner, Head of Technology Investment Banking), who was supported by Priyanshu Bhattacharya (Director), Claire Liu (Associate), and Fabian Kotek (Analyst). “We are delighted to have supported DYPHOX in this transaction which is an important next step in becoming the gold-standard for antimicrobial coating”, said Dr. Nicholas Hanser.